… overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
… study To our knowledge, INSIGHT is the first randomised study to compare tepotinib plus
gefitinib … patients with NSCLC who have received first-line erlotinib, gefitinib, afatinib, or icotinib; …
gefitinib … patients with NSCLC who have received first-line erlotinib, gefitinib, afatinib, or icotinib; …
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
TH Kim, JH Choi, MS Ahn, HW Lee, SY Kang, YW Choi… - BMC cancer, 2024 - Springer
… at our institution were retrospectively identified. The eligibility … study cohort were included
in previous retrospective studies … four patients who received gefitinib in a clinical trial as a first-…
in previous retrospective studies … four patients who received gefitinib in a clinical trial as a first-…
Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer
O Aren, S Samtani, M Frelinghuysen… - American Journal of …, 2021 - journals.lww.com
… , gefitinib, and erlotinib have been proven to be highly effective in this subgroup of patients.
… , our retrospective study demonstrates that a reduced dose of 75 mg/d of erlotinib could be …
… , our retrospective study demonstrates that a reduced dose of 75 mg/d of erlotinib could be …
An observational study to assess the molecular epidemiology and direct medical costs of epidermal growth factor receptor (EGFR) mutations in patients with advanced …
G Mountzios, S Lampaki, GA Koliou… - Lung Cancer: Targets …, 2021 - Taylor & Francis
… -interventional, multicenter, retrospective cohort study, based … it exerts higher activity than
erlotinib or gefitinib, albeit some … -generation inhibitors, including erlotinib and gefitinib, and is …
erlotinib or gefitinib, albeit some … -generation inhibitors, including erlotinib and gefitinib, and is …
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
K Jiang, L Wu, X Zheng, Y Xu, Q Miao, X Zheng… - BMC Pulmonary …, 2024 - Springer
… Here we conducted a retrospective multi-center study to explore … The combination of Tepotinib
and Gefitinib has reported an … erlotinib could not reverse the AR to EGFR-TKI [40]. In our …
and Gefitinib has reported an … erlotinib could not reverse the AR to EGFR-TKI [40]. In our …
Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
C Zhang, H Cao, Y Cui, S Jin, W Gao… - Thoracic …, 2021 - Wiley Online Library
… to gefitinib or erlotinib. The median PFS was 8.0 months (95% CI: 4.9–9.5 months). Our …
single-center retrospective study with a small sample size. Prospective multicenter studies with a …
single-center retrospective study with a small sample size. Prospective multicenter studies with a …
Concomitant radiotherapy and TKI in metastatic EGFR-or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group
P Borghetti, ML Bonù, R Giubbolini, NG Levra… - La radiologia …, 2019 - Springer
… We therefore conducted a multicentric retrospective study that aimed to investigate the …
Fifty-nine patients were treated with Gefitinib, 19 with Erlotinib, 18 with Crizotinib and 10 with …
Fifty-nine patients were treated with Gefitinib, 19 with Erlotinib, 18 with Crizotinib and 10 with …
… of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter …
SH Lee, YC Lin, LC Chiu, JS Ju… - Therapeutic …, 2022 - journals.sagepub.com
… study, we sought to perform a retrospective multicenter clinical analysis that compares the
efficacy, safety, and acquired resistance of first-line afatinib or erlotinib … gefitinib or erlotinib as …
efficacy, safety, and acquired resistance of first-line afatinib or erlotinib … gefitinib or erlotinib as …
… growth factor receptor mutation status and response to tyrosine kinase inhibitors in advanced Chinese female lung squamous cell carcinoma: a retrospective study
Q Chang, H Qiang, J Qian, Y Lei, J Lu, H Feng… - Frontiers in …, 2021 - frontiersin.org
… We retrospectively collected and analyzed the data of patients who had been confirmed …
Of these patients, 36 received first-generation TKIs (16 gefitinib, 14 icotinib and 6 erlotinib) …
Of these patients, 36 received first-generation TKIs (16 gefitinib, 14 icotinib and 6 erlotinib) …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
… Citation64 In a retrospective, population-based study of 467 patients with advanced NSCLC
… 14.0 months with gefitinib and erlotinib, respectively (P=0.001). Citation63 In this study, the …
… 14.0 months with gefitinib and erlotinib, respectively (P=0.001). Citation63 In this study, the …